SLXN Latest Press Releases

-- September 30, 2026 --

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer Globe Newswire 8:00 AM

-- September 29, 2026 --

Silexion Therapeutics Announces Exercise of Warrants Globe Newswire 8:03 AM

-- September 28, 2026 --

Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers Globe Newswire 8:30 AM

-- September 9, 2026 --

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences Globe Newswire 9:00 AM

-- August 14, 2026 --

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 8:45 AM

-- August 11, 2026 --

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering Globe Newswire 8:01 PM

-- August 4, 2026 --

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers Globe Newswire 9:15 AM

-- July 29, 2026 --

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center Globe Newswire 7:00 AM

-- June 23, 2026 --

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer Globe Newswire 8:40 AM

-- June 16, 2026 --

Silexion Therapeutics to Attend BIO International Convention 2026 Globe Newswire 4:30 PM

Market Data Delayed 15 Minutes